SINIL PHARMACEUTICAL Co., Ltd.
KKRX:0127906,140.00
KRW
-150.00
(-2.38%)
ISIN
KR7012790002
Return %
Stock
S&P 500
1Y
2.85
14.39
3Y
-4.81
81.42
5Y
-48.21
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jae-Hyun Hong
- Full Time Employees
- 413
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Chungju-si South Korea
- IPO Date
- Aug 13, 1999
- Similar Companies
- Business
- SINIL PHARMACEUTICAL Co., Ltd. is a South Korea-based pharmaceutical company that develops, manufactures, and markets finished pharmaceutical formulations, over-the-counter medicines, functional cosmetics, and veterinary healthcare products. Founded in 1971 and incorporated in 1977, the company is headquartered in Chungju-si, Chungcheongbuk-do, South Korea, and is listed on the KOSDAQ under the ticker 012790. The company operates across multiple specialized product categories and therapeutic segments: topical pain relief and anti-inflammatory formulations, including transdermal drug delivery systems, nonsteroidal anti-inflammatory drug (NSAID) hydrogel cataplasms, and medicated adhesive plasters anchored by its flagship Defen Plaster (diclofenac sodium) brand family; prescription therapeutics (ETC), covering cardiovascular and metabolic agents, hyperlipidemia and antihypertensive treatments, antidiabetic formulations, gastrointestinal drugs, central nervous system medications, antihistamines, and respiratory remedies; over-the-counter (OTC) healthcare products, comprising oral analgesics, antipyretics, cough suppressants, topical dermatological treatments, cold remedies, and folic acid supplements; health functional foods and dietary nutritional supplements, including multivitamins and wellness products; derma-cosmetics and functional skincare formulations sold under its proprietary Farmtree brand; veterinary medicines for animal health management; and contract development and manufacturing organization (CDMO) and toll manufacturing services for domestic and international pharmaceutical partners. In recent developments, Sinil Pharmaceutical has strategically expanded its operational footprint and product portfolio to accelerate revenue growth and diversify beyond its traditional topical plaster foundation. The company has intensified its focus on ethical pharmaceuticals (ETC) by broadening its distribution networks through specialized contract sales organizations (CSOs) and advancing its internal research and development pipeline. Recent regulatory and commercialization milestones include the completion of development and rollout preparations for multi-drug prescription formulations, including antidiabetic combinations such as Forsigly Duo SR and Traglipitin, cardiovascular therapies including Aquis, and clinical pipeline candidates spanning hyperlipidemia (SIL1122), hypercholesterolemia (SIL1123), and rhinitis (SIL1406). Furthermore, the company has completed leadership succession and governance consolidation under Chief Executive Officer Jae-Hyun Hong and continues to optimize its Korea Good Manufacturing Practice (KGMP)-certified manufacturing and automated warehouse infrastructure in Chungju to expand output capacity for domestic distribution and global export markets.